Vaccine promising against disease-causing HPV

	Tweet

Certain strains of the virus responsible for causing Genital Warts—human papillomavirus or HPV—are also likely to trigger Cervical cancer. Now comes news that a vaccine designed to combat four of these strains can dramatically reduce persistent infection and the risk of developing warts and cancer.

The findings are similar to results seen when a two-hit vaccine was tested in North America and Brazil last year. However, in that study, the vaccine targeted only HPV-16 and HPV-18, the main cancer-causing types, whereas the new four-strain ‘quadrivalent’ vaccine targets these types as well as HPV-6 and HPV-11, the ones most often linked to genital warts.

The study involved 552 young women who were not pregnant, had no history of abnormal Pap smears, and had had no more than four sexual partners. Women with previous HPV infection were not excluded from the study.

The women were given three shots of the quadrivalent vaccine or placebo injections over a period of six months. They were then followed for 36 months with regular gynecologic exams, cervical testing for HPV, and Pap smear tests.
-------------------------
Condylox is a the first ever FDA approved gel that treats genital warts. The active ingredients in Condylox get right to the problem and start treating your genital warts immediately.

Order Condilox Online
-------------------------
Compared with placebo injections, the vaccine led to 90 percent fewer cases of persistent infection or disease due to HPV types 6, 11, 16, or 18, lead study author Dr. Luisa L. Villa, from the Ludwig Institute for Cancer Research in Sao Paulo, Brazil, and colleagues report in the medical journal Lancet Oncology.

The vaccine was 89 percent effective in preventing infection with the four HPV types, and 100 percent effective in preventing the diseases associated with these types, the investigators point out.

As well as preventing clinical disease caused by common HPV types, the vaccine was generally well tolerated, the authors state. “Large-scale studies are under way.”

The study was funded by Merck Research Laboratories, which is developing the vaccine.

SOURCE: Lancet Oncology, online April 7, 2005.

RELATED STORIES:
World unprepared for avian flu, experts warn   Hepatitis A test often misleading   Drug-resistant TB killed 150,000 in 2008   Discovery of New Infectious Diseases - Bartonella Species   Rare gay male sex disease enters Britain: report   Lavender oil has potent antifungal effect   Childhood Vaccination Rates Remain High in U.S.   WHO hopes clean water guide helps prevent disease   Intrathecal Medication Therapy Effective for Painful Post-Herpetic Neuralgia Caused by Shingles   Health workers often decline TB treatment   Drug-resistance fears for deadly fungal disease   Groundbreaking research into some of the most deadly antibiotic-resistant diseases

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]